Pulmonary hypertension (PH), particularly pulmonary arterial hypertension (PAH), is a rare but life-threatening disorder. Commercial interest in PH/PAH has increased recently due to significant advances in the understanding of its etiology and pathophysiology, and the emergence of new therapies to treat it. Despite the relatively small patient population in the major pharmaceutical markets, the PAH therapy market is a billion-dollar market that is expected to increase over the coming decade. Our new Current Treatment content provides deep insights into the current treatment of PH/PAH in the United States, and the factors behind those treatment decisions.

Questions Answered:

  • What impact have the launches of novel therapies such as Uptravi, Orenitram, and Adempas, had on prescribing behavior for PH and PAH?
  • What influence has the positive Phase III AMBITION trial, evaluating the upfront dual combination therapy of Letairis and Adcirca, had on the treatment algorithm for PAH?
  • How are specialists utilizing PAH therapies for the treatment of PHWHO groups 2-5?
  • What factors and drug therapy attributes are driving prescribing behavior for the treatment of PAH/PH?


Markets covered: United States

Methodology: Surveys of 51 cardiologists and 53 pulmonologists in the United States, completed in January 2017.

Indication coverage: Pulmonary Hypertension (PH) and Pulmonary Arterial Hypertension (PAH).

Key drugs covered: Uptravi, Orenitram, Adempas, Opsumit, Letairis, Adcirca, Bosentan, Revatio, Tyvaso, Remodulin, Veletri, Flolan.

Key companies mentioned: Actelion, Bayer, Gilead, GlaxoSmithKline, United Therapeutics.

Table of contents

  • Detailed, Expanded Analysis (U.S.)
    • Key updates
      • November 2017
      • August 2017
    • Introduction to Current Treatment for Pulmonary Hypertension
      • Key Findings
      • Introduction to Current Treatment and Medical Practice for Pulmonary Hypertension
    • Physician Prescribing Practices
      • Key Findings
      • Patient Characteristics
        • PAH Patients Are a Relatively Small But Commercially Important Group of PH Patients
      • Treatment Practices
        • Oral PAH Therapies Dominate Early Lines of Treatment
        • Time to Treatment Start
        • Treatment Rates
        • Patient Share by Product
        • Treatment Duration by Product
        • Use of Nonpharmacological Approaches
        • Line of Therapy Analysis
        • Combination/Regimen/Comedication Analysis
      • Persistency and Compliance
        • The Nature of PAH Leads to Relatively High Patient Compliance
      • Sequencing of Treatment
        • Combination Therapy Is Frequently Prescribed to PAH Patients
      • Recent and Anticipated Changes in Brand Use/Treatment Approach
        • Increasing Combination Therapy and Reduced Market Access Hurdles Are Driving Changes in Prescribing
    • Physician Insight on Medical Practice
      • Key Findings
      • Drivers of Treatment Selection
        • Safety and Tolerability Are Key Factors in Prescribing of PAH Therapies
        • Factors Influencing Treatment and Disease Management
        • Major Drivers of Brand Use/Treatment
        • Major Obstacles to Brand Use/Treatment
        • Treatment Failure/Brand Issues
    • Methodology
      • Primary Market Research Methodology
    • Appendix
      • Primary Market Research

Author(s): Alexandra Hemsley

Alexandra Hemsley, , is a business insights analyst with the cardiovascular, metabolic, and renal disorders team at Decision Resources, where she primarily focuses on commercial developments in the drug markets for pulmonary hypertension, atrial fibrillation, venous thromboembolism, and osteoporosis. Before joining Decision Resources Group, Alexandra completed an in biochemical engineering and bioprocess leadership at University College London, where she investigated the effect of force and shear on embryonic stem cells and the implications for bioprocessing for regenerative medicine therapies. After completing her doctorate, Alexandra worked as an editor with the Future Science Group, where her responsibilities included market research and competitor analysis, editorial board recruitment, content development, and management of the peer review process. Alexandra also holds an in biochemical engineering from University College London and a in biological sciences from the University of Southampton.

Related Reports

Pulmonary Hypertension | Current Treatment | Detailed, Expanded Analysis (EU5)

Pulmonary hypertension (PH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Off-label drug use is widespread because drugs have been approved only for the...

View Details

Pulmonary Hypertension | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Pulmonary Arterial Hypertension (US)

Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder marked by considerable morbidity and mortality. A wide array of dr...

View Details

Pulmonary Hypertension | Landscape & Forecast | Disease Landscape & Forecast

Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the disease’s rarity, the p...

View Details

Pulmonary Hypertension | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key pulmonary hypertension pat...

View Details